CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki, François; Lionet, Arnaud; Buob, David; Labalette, Myriam; Allorge, Delphine; Provôt, François; Hazzan, Marc; Noël, Christian; Broly, Franck; Cauffiez, Christelle.
Nephrol Dial Transplant
; 26(9): 3046-50, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21677300
Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.
The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.
Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.